Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics to Participate in Upcoming Investor Conferences